The attitude and practice of general surgeons toward cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A cross-sectional study
| Autor: | Shahad N. AlAnazi, Sulaiman A. Al-Shammari, Abdullah M. Albdah, Wadha S. AlOtaibi, Noura S. Alhassan, Thamer Bin Traiki, Mashal M. Alnmry |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hyperthermic intraperitoneal chemotherapy (HIPEC)
medicine.medical_specialty Cross-sectional study Group B 03 medical and health sciences 0302 clinical medicine medicine Gastrointestinal cancer General surgery business.industry Cancer General Medicine medicine.disease Peritoneal carcinomatosis (PC) Peritoneal carcinomatosis surgical procedures operative Oncology 030220 oncology & carcinogenesis Referral system Cross-sectional Study 030211 gastroenterology & hepatology Surgery Hyperthermic intraperitoneal chemotherapy Cytoreductive surgery (CRS) Cytoreductive surgery business |
| Zdroj: | Annals of Medicine and Surgery |
| ISSN: | 2049-0801 |
| Popis: | Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) mandate well-established HIPEC and oncology centers, which are not available in many medical institutions. This study assessed the knowledge, attitude, and practice toward CRS and HIPEC of general surgeons in Riyadh, Saudi Arabia. Patients and methods General surgeons (n = 266) from nine hospitals who treat patients with gastrointestinal cancer were surveyed. The responses of surgeons who work in HIPEC and academic centers (Group A) and surgeons working in tertiary and secondary hospitals (Group B) were compared. The survey response rate was 48.1% (128/266). Results Surgeons in group B treated significantly more patients with peritoneal carcinomatosis per year than surgeons in group A (P = .001). Group B reported having a HIPEC specialist at their hospital, and 71.4% reported that the nearest HIPEC center was within 30 miles, compared to 4.5% of respondents in group A (P = .001). Lack of access to a HIPEC specialist was reported by 15.5% of surgeons in group B and 0% of surgeons in group A (P = .006). HIPEC as a possible therapeutic option for appendiceal cancer was cited by 60.7% of surgeons in group B compared to 84.1% of surgeons in group A (P = .007) and as a therapeutic option for ovarian cancer by 52.4% of surgeons in group B and 81.8% of surgeons in group A (P = .001). Conclusion New strategies are needed to improve the knowledge and implementation of the referral system for HIPEC among general surgeons. Our study was limited by a low response rate. Highlights ● Exposure to HIPEC centers during residency or fellowship training was reported by half of our respondents. ● Surgeons in tertiary and secondary hospitals treated significantly more patients with peritoneal carcinomatosis per year than surgeons in HIPEC and academic centers. ● Lack of access to a HIPEC specialist was significantly reported by surgeons working in tertiary and secondary hospitals. ● HIPEC was significantly cited as an option for appendiceal cancer by surgeons in HIPEC and academic centers compared to surgeons in tertiary and secondary hospitals. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|